DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Zepbound (tirzepatide) for chronic weight management and OSA with obesity. State telehealth scope, insurance coverage, and verified providers serving New York residents.
For weight-loss indication, NY Medicaid coverage is covers. NY Medicaid comprehensive; PA approval high for documented obesity. Zepbound requires the weight-loss PA pathway; review NY Medicaid criteria carefully.
Most New York commercial plans cover Zepbound with prior authorization. PA criteria typically require BMI ≥ 30 (or ≥ 27 with comorbidity) for weight-loss-indicated drugs, or T2D diagnosis with metformin trial for diabetes-indicated drugs. Step therapy requirements vary by plan.
White-glove telehealth focused on speed and ease. Strongest pick for patients paying cash who want a fast time-to-prescription path with minimal friction.
Built around medical depth. Best for patients with commercial insurance who want a team that fights insurance battles and treats GLP-1 as part of a comprehensive obesity care plan.
If insurance denies, the New York cash-pay route is LillyDirect vials ($349-499/mo depending on dose). Available nationally; ships to New York residents through manufacturer-direct fulfillment.
Editorial summary. New York licensure and insurance rules change quarterly; confirm with your prescriber and plan before relying on any single source. Affiliate disclosure: we earn commission on outbound clicks to provider partners.